Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.

The transaction will allow 23andMe, which 澳洲幸运5官方开奖结果体彩网:filed for Chapter 11 bankruptcy in March, to continue providing consumer genome services uni🅠nterrupted.

Regeneron pledged to “prioritize the privacy, security and ethical use of 2𝔍3andMe’s customer data” and said it will work with a court-appointed official to review its security practices. The deal is expected to close in the third quarter, pending bankruptcy court and regulatory approvals.

For Regeneron, the move is meant to aid its genetic research. “We believe we can help 23andMe deliver and build upon its mission… while furthering R🐻egeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall,” Chief Science Officer George Yancopoulos said. 

Shares of Regeneron edged 0.4% lower in recent trading and are down about 17% for 2025.